The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention

Cellular and Molecular Immunology

Volumn 5, Issue 1, 2008, Pages 1-7

  Luo, Cheng ^a,c   Wang, Kou ^a   Liu, Dequan ^b   Li, Yan ^a   Zhao, Qinshi ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b Tumor Hospital of Yunnan Province   (China)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

cholesterol; lipid raft; liquid crystal phase; liquid ordered phase; virus assembly

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE LIPID; PEPTIDE FRAGMENT;

AUTOIMMUNE DISEASE; CELL MEMBRANE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; T LYMPHOCYTE; ULTRASTRUCTURE; VIROLOGY; VIRUS ASSEMBLY; VIRUS ENTRY;

ANTICHOLESTEREMIC AGENTS; AUTOIMMUNE DISEASES; CELL MEMBRANE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VIRUS ASSEMBLY; VIRUS INTERNALIZATION;

EID: 47049106121     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.1     Document Type: Review

References (39)

1. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science. 1972;175:720-731.
2. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell. 1992;68:533-544.
3. Simons K, Ikon (Pubitemid 27248754)
4. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 1998;166:4773-4779.
5. Pike LJ, Han X, Chung KN, Gross RW. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry. 2002;41:2075-2088. (Pubitemid 34132282)
6. Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. R (+)- Methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun. 2004;324:621-626. (Pubitemid 39345561)
7. Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, Shaw AS. T cell receptor signaling precedes immunological synapse formation. Science. 2002;295:1539-1542. (Pubitemid 34174012)
8. Kupfer A. Breaking up receptor alliances: the parting of CD3 and CD4. Nat Med. 2000;6:1097-1098.
9. Gordy C, Mishra S, Rodgers W. Visualization of antigen presentation by actin-mediated targeting of GEM domains to the immune synapse of antigen presenting cells. J Immunol. 2004; 172:2030-2038. (Pubitemid 38182348)
10. Fragoso R, Ren D, Zhang X, Su MW, Burakoff SJ, Jin YJ. Lipid raft distribution of CD4 depends on its palmitoylation and association with Lck, and evidence for CD4-induced lipid raft aggregation as an additional mechanism to enhance CD3 signaling. J Immunol. 2003;170:913-921. (Pubitemid 36070545)
11. Vincent N, Genin C, Malvoisin E. Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochimi Biophys Acta. 2002; 1567:157-164. (Pubitemid 35454057)
12. Chandok MR, Farber DL. Farber Signaling control of memory T cell generation and function. Semin Immunol. 2004;16:285-293. (Pubitemid 39446556)
13. van Gool SW, Barcy S, Devos S, et al. CD80 (B7-1) and CD86 (B7-2): Potential targets for immunotherapy? Res in Immunol. 1995;146:183-196.
14. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG. Crystal structure of cholera toxin B-pentamer bound to receptor GMl pentasaccharide. Protein Sci. 1994;3:166-175. (Pubitemid 24086350)
15. Rouquette-Jazdanian AK, Pelassy C, Breittmayer JP, Aussel C. Full CD3/TCR activation through cholesterol-depleted lipid rafts. Cell Signal. 2007;19:1404-1418. (Pubitemid 46824174)
16. Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol. 2003;170:1329-1338. (Pubitemid 36139500)
17. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci. 2002;115:2603-2611. (Pubitemid 34778077)
18. Luo C, Peng Y, Santti R, He ML, Lin MC. COX-1 and -2 expressions in sex-related organs of neonatally estrogen treated rats and in activated and non-activated macrophage RAW264.7 cells with phytoestrogen. Endorine. 2006;29:161-167. (Pubitemid 43780360)
19. Luo C, He ML, Bohlin L. Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial. Acta Pharmacol Sin. 2005;26:926-933. (Pubitemid 41153212)
20. Fülöp T Jr, Larbi A, Dupuis G, Pawelec G. Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther. 2003;5:290-302. (Pubitemid 37407979)
21. Pietiäinen VM, Marjomäki V, Heino J, Hyypiä T. Viral entry, lipid rafts and caveosomes. Ann Med. 2005;37:394-403. (Pubitemid 41476125)
22. Popik W, Alce TM, Au WC. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J Virol. 2002;76:4709-4722. (Pubitemid 34441677)
23. Li H, Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino-acid sequence and consensus pattern. Endocrinology. 1998;139:4991-4997. (Pubitemid 28533447)
24. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses. 2001;17:1009-1019. (Pubitemid 32881320)
25. Echarri A, González ME, Carrasco L. Human immunodeficiency virus (HIV) Nef is an RNA binding protein in cell-free systems. J Mol Biol. 1996;262:640-651. (Pubitemid 26343512)
26. Ono A, Waheed AA, Joshi A, Freed EO. Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol. 2005;79:14131-14140. (Pubitemid 41552711)
27. Fournier C, Cortay JC, Carbonnelle C, Ehresmann C, Marquet R, Boulanger P. The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro. Virus Genes. 2002;25: 253-267.
28. Huttner WB, Zimmerberg J. Implications of lipid microdomains for membrane curvature, budding and fission. Curr Opin Cell Biol. 2001;13:478-484. (Pubitemid 32709772)
29. Maziere JC, Landureau JC, Giral P, et al. Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother. 1994;48:63-67. (Pubitemid 24113551)
30. Tritel M, Resh MD. The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process. J Virol. 2001;75:5473-5481. (Pubitemid 32488140)
31. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipidenriched membrane lipid rafts. J Virol. 2000;74:3264-3272. (Pubitemid 30143751)
32. Lindwasser OW, Resh MD. Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc Natl Acad Sci U S A. 2002;99:13037-13042.
33. Esser MT, Graham DR, Coren LV, et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: Implications for viral pathogenesis and immune regulation. J Virol. 2001;75:6173-6182. (Pubitemid 32553148)
34. Bécart S, Setterblad N, Ostrand-Rosenberg S, Ono SJ, Charron D, Mooney N. Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling. J Cell Sci. 2003;116:2565-2575. (Pubitemid 36790137)
35. O'Brien WA, Chen IS, Ho DD, Daar ES. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol. 1992;66:3125-3130.
36. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A. 2002;99:16249-16254. (Pubitemid 35462781)
37. Heredia A, Gilliam B, Latinovic O, et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother. 2007;51:2489-2496. (Pubitemid 47047328)
38. Ryser HJ, Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov Today. 2005;10:1085-1094.
39. Blazevic V, Männik A, Malm M, et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses. 2006;22:667-677. (Pubitemid 44061403)